On Target for 400m Tonnes of Decarbonisation - Carbon13 Closes Successful Seed Round of Over $2.2m
Carbon13, the venture builder for the climate emergency, is today announcing the close of its latest seed round, resulting in over $2.2m.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230719330116/en/
L-R, Jonathan Cumming, Chief Financial Officer & Managing Director, Dr Chris Coleridge, Founder & CEO, Dr Nicky Dee, Co-founder & Chief Sustainability and Innovation Officer, Michael Langguth, Co-founder & Chief Strategy Officer (Photo: Business Wire)
The new funding is set to boost Carbon13’s operations significantly and propel Carbon13’s current and future ventures towards the key target of 400 million tonnes of decarbonisation.
The successful funding round was made possible thanks to a range of family offices and venture firms, including True Ventures, a Silicon Valley-based venture capital firm focused on early stage technology startups.
The new injection of funding for Carbon13 will enable a significant increase in climate startup production and a scaling of ambition. Currently, Carbon13 ventures possess an annual mitigation potential of over 420 million tonnes of CO2e – this potential is now set to rise further, as is the number of invested ventures built through Carbon13 programmes since 2021 (currently 46).
In addition, since 2021, Carbon13 has now supported over 350 startup founders through its three programmes (Venture Builder Europe, Venture Builder UK, and Venture Launchpad). This number is also set to grow significantly thanks to the new funding. By end of 2025, Carbon13's Venture Builder is on course to support over 1,000 entrepreneurs to build at least 200 startups.
Commenting on the successful funding round, CEO and Founder of Carbon13, Chris Coleridge, said: “This investment from True Ventures and four family offices is crucial to Carbon13’s plans for scaling our support to entrepreneurs tackling the most urgent global challenges in decarbonisation and carbon capture.
Climate change is not just a scientific challenge, it is not just a business innovation challenge, it is also a people challenge. We have found that remarkable things happen when you bring together some of the world’s most talented people who are all highly motivated by the mission to fight the climate emergency. True's investment is therefore a valuable recognition of our people-first approach.
I'm also delighted that Carbon13 is joining True's community of decarbonisation startups. Launching and scaling ventures with credible claims to significant emissions mitigation was a foundational principle when I was developing Carbon13 with my cofounders. Again, it is our people-first approach which drives this, as our programmes inculcate carbon intelligence within the founding team to empower them to make strategic decisions based as much on carbon reduction as on commercial value. Ultimately, in the world of Net Zero 2050, there will be no distinction between the two.”
Also commenting, Priscilla Tyler, Vice President at True Ventures, said: “Our investment in Carbon13 and its focused support of carbon-neutralizing technology is an incredible complement to our portfolio of climate tech investments. What’s more, the Carbon13 team aligns deeply with our values and belief in the creative entrepreneur. They invest in people first and tech second. We’re thrilled for this partnership and to help embolden their important work around mitigating climate change.”
- ENDS -
About Carbon13
Carbon13 is the Venture Builder for the Climate Emergency. Since 2021, three programmes of the Venture Builder Europe, Venture Builder UK, and Venture Launchpad, have invested in 46 startups, and worked with over 350 founders. Carbon13 grew out of the Cambridge ecosystem of technology, academia and innovation, and has expanded to Berlin, our new base in the EU. Notable Carbon13 alumni include Kita, Infyos, Nium, Biozeroc, Materials Nexus and Tierra Foods. Kita and Tierra Foods are both nominated for Earthshot 2023 prizes.
Carbon13 media pack available here: https://carbonthirteen.com/media/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230719330116/en/
Contact information
PR and enquiries
contact
Dark Green PR
Tel: +44 (0)7940 968704
team@darkgreenpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CORRECTING and REPLACING PHOTO Decode the Future of AI and Customer Experience at Elevate'25 Digital Innovation Summit18.9.2025 21:23:00 EEST | Press release
Please replace the photo with the accompanying corrected photo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918928987/en/ Gain insight and advice from firms at the frontier of AI-powered, mobile-first customer experiences. The release reads: DECODE THE FUTURE OF AI AND CUSTOMER EXPERIENCE AT ELEVATE'25 DIGITAL INNOVATION SUMMIT With keynotes from Google Cloud and an independent research firm, Elevate’25 will provide actionable strategies to harness the power of AI and create exceptional experiences for today's mobile-first consumer As unprecedented advancements in AI reshape consumer behavior, digital innovation summit Elevate'25 opened for general registration today. Sponsored by Airship, the exclusive, one-day event is designed to equip business leaders with proven strategies to harness artificial intelligence and mobile-first technology for a decisive competitive advantage. Taking place on October 15, 2025, at the i
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 19:22:00 EEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release
Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release
AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by
illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release
illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom